GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Surface Oncology Inc (NAS:SURF) » Definitions » Net Change in Cash

Surface Oncology (Surface Oncology) Net Change in Cash : $-61.58 Mil (TTM As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Surface Oncology Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Surface Oncology's Net Change in Cash for the three months ended in Jun. 2023 was $-15.74 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2023 was $-61.58 Mil.

Surface Oncology Net Change in Cash Historical Data

The historical data trend for Surface Oncology's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surface Oncology Net Change in Cash Chart

Surface Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Change in Cash
Get a 7-Day Free Trial 60.57 -35.76 128.39 -119.10 -5.14

Surface Oncology Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.17 -9.73 -14.19 -21.93 -15.74

Surface Oncology Net Change in Cash Calculation

Surface Oncology's Net Change in Cash for the fiscal year that ended in Dec. 2022 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-59.552+22.757+31.66+0
=-5.14

Surface Oncology's Net Change in Cash for the quarter that ended in Jun. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-19.561+32.071+-28.245+0
=-15.74

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-61.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Surface Oncology Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Surface Oncology's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Surface Oncology (Surface Oncology) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Surface Oncology Inc (NAS:SURF) » Definitions » Net Change in Cash
Comparable Companies
PRTK DARE SQZ LJPC CLVS CSBR DTIL CRTX EVLO FNCH OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX HKSE:02269 SGEN SZSE:300122
Traded in Other Exchanges
N/A
Address
50 Hampshire Street, 8th Floor, Cambridge, MA, USA, 02139
Website
https://www.surfaceoncology.com
Surface Oncology Inc is a clinical-stage immuno-oncology company. It is developing new therapies that modify the spaces in and around tumors in the tumor microenvironment to create conditions that support and sustain anti-tumor immune responses. The company's pipeline products are SRF231, SRF373, SRF617, and SRF388. Geographically, the activities are carried out throughout the region of the United States.
Executives
Chandra Adams officer: Deputy GC SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Alison Oneill officer: Chief Medical Officer
Jessica Fees officer: See Remarks C/O SURFACE ONCOLOGY, ICN., 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA 02139
Robert W. Ross officer: Chief Medical Officer C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Henry C. Rath officer: Chief Business Officer C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET 8TH FL, CAMBRIDGE MA 02139
Vito J. Palombella officer: Chief Scientific Officer 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Carsten Brunn director C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Theresa Boni officer: General Counsel C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Benjamin Hickey director C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121
Liisa I Nogelo officer: General Counsel C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA 02139
Jeff Goater director, officer: Chief Executive Officer C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Denice Torres director 3 RABBIT RUN DRIVE, NEW HOPE PA 18938
David S. Grayzel director C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Ix, L.p. 10 percent owner 46 WAREHAM STREET, FLOOR 3, BOSTON MA 02118
Atlas Venture Associates Ix, Llc 10 percent owner 56 WAREHAM STREET, FLOOR 3, BOSTON MA 02118

Surface Oncology (Surface Oncology) Headlines

From GuruFocus

Surface Oncology to Participate in the Gilmartin Group Emerging Growth Company Showcase

By PurpleRose PurpleRose • 08-24-2022

Surface Oncology to Participate in the Cowen 43rd Annual Health Care Conference

By sperokesalga sperokesalga • 02-28-2023

SURFACE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surface Oncology, Inc. - SURF

By Business Wire • 08-07-2023

Surface Oncology Announces Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular Carcinoma

By GuruFocusNews GuruFocusNews • 07-10-2022

Surface Oncology to Participate in Upcoming Investor Conferences

By PurpleRose PurpleRose • 07-11-2022

Shareholder Alert: Ademi LLP investigates whether Surface Oncology, Inc. has obtained a Fair Price in its transaction with Coherus

By PRNewswire PRNewswire • 06-16-2023

Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors

By Stock market mentor Stock market mentor • 01-05-2023

Surface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023

By sperokesalga sperokesalga • 04-18-2023

Surface Oncology to Present Non-clinical Data for SRF388 and SRF114 at the Society for Immunotherapy of Cancer 2022 Annual Meeting

By Value_Insider Value_Insider • 11-07-2022

Surface Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

By PurpleRose PurpleRose • 07-13-2022